Dopamine	B:C0013030
modulates	O
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	B:C0443264
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	B:C0004112
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	B:C0206116
activity	O
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	O
activity	B:C0007613
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	B:C0027836
renin-angiotensin	O
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	B:C0035096
system	I:C0035096
in	O
cultures	O
.	O

Dopamine	O
modulates	O
astroglial	O
and	O
microglial	O
activity	O
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
in	O
cultures	B:C0040284
.	O

Dopamine	B:C0013030
is	O
an	O
immunomodulatory	O
molecule	I:C1527392
that	O
acts	O
on	O
immune	O
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	O
and	O
peripheral	O
tissues	O
.	O

Dopamine	O
is	O
an	O
immunomodulatory	B:C1527392
molecule	I:C1527392
that	O
acts	O
on	O
immune	O
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	O
and	O
peripheral	O
tissues	O
.	O

Dopamine	O
is	O
an	O
immunomodulatory	O
molecule	I:C1527392
that	O
acts	O
on	O
immune	B:C0312740
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	O
and	O
peripheral	O
tissues	O
.	O

Dopamine	O
is	O
an	O
immunomodulatory	O
molecule	I:C1527392
that	O
acts	O
on	O
immune	O
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	B:C3714787
and	O
peripheral	O
tissues	O
.	O

Dopamine	O
is	O
an	O
immunomodulatory	O
molecule	I:C1527392
that	O
acts	O
on	O
immune	O
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	O
and	O
peripheral	B:C0205100
tissues	O
.	O

Dopamine	O
is	O
an	O
immunomodulatory	O
molecule	I:C1527392
that	O
acts	O
on	O
immune	O
effector	I:C0312740
cells	I:C0312740
both	O
in	O
the	O
CNS	O
and	O
peripheral	O
tissues	B:C0040300
.	O

However	O
,	O
the	O
role	O
of	O
changes	O
in	O
dopamine	B:C0201989
levels	I:C0201989
in	O
the	O
neuroinflammatory	O
response	O
is	O
controversial	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	B:C0035096
system	I:C0035096
(	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	I:C1155266
in	O
peripheral	O
tissues	O
and	O
brain	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	O
system	I:C0035096
(	O
renin-	B:C0035096
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	I:C1155266
in	O
peripheral	O
tissues	O
and	O
brain	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	O
system	I:C0035096
(	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	B:C1155266
processes	I:C1155266
in	O
peripheral	O
tissues	O
and	O
brain	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	O
system	I:C0035096
(	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	I:C1155266
in	O
peripheral	B:C0205100
tissues	O
and	O
brain	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	O
system	I:C0035096
(	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	I:C1155266
in	O
peripheral	O
tissues	B:C0040300
and	O
brain	O
.	O

The	O
local	O
/	O
paracrine	O
renin-angiotensin	O
system	I:C0035096
(	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
)	O
plays	O
a	O
major	O
role	O
in	O
inflammatory	O
processes	I:C1155266
in	O
peripheral	O
tissues	O
and	O
brain	B:C0006104
.	O

In	O
the	O
present	O
study	B:C0008972
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	O
inflammatory	O
responses	I:C1155266
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	B:C0006104
renin-	O
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	O
inflammatory	O
responses	I:C1155266
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
renin-	B:C0035096
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	O
inflammatory	O
responses	I:C1155266
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	B:C0013030
on	O
the	O
glial	O
inflammatory	O
responses	I:C1155266
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	B:C0027836
inflammatory	O
responses	I:C1155266
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
possible	O
role	O
of	O
the	O
brain	O
renin-	O
angiotensin	I:C0035096
system	I:C0035096
in	O
the	O
effects	O
of	O
dopamine	O
on	O
the	O
glial	O
inflammatory	B:C1155266
responses	I:C1155266
.	O

Astrocytes	B:C0004112
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	I:C0033665
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
(	O
angiotensin	O
II	I:C0003009
)	O
in	O
the	O
brain	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	B:C0033665
protein	I:C0033665
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
(	O
angiotensin	O
II	I:C0003009
)	O
in	O
the	O
brain	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	I:C0033665
angiotensinogen	B:C0003017
and	O
angiotensin	O
II	I:C0003009
(	O
angiotensin	O
II	I:C0003009
)	O
in	O
the	O
brain	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	I:C0033665
angiotensinogen	O
and	O
angiotensin	B:C0003009
II	I:C0003009
(	O
angiotensin	O
II	I:C0003009
)	O
in	O
the	O
brain	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	I:C0033665
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
(	O
angiotensin	B:C0003009
II	I:C0003009
)	O
in	O
the	O
brain	O
.	O

Astrocytes	O
are	O
the	O
major	O
source	O
of	O
the	O
precursor	O
protein	I:C0033665
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
(	O
angiotensin	O
II	I:C0003009
)	O
in	O
the	O
brain	B:C0006104
.	O

Neurotoxins	B:C0027934
such	O
as	O
MPP	O
(+)	O
(	O
1	O
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
.	O

Neurotoxins	O
such	O
as	O
MPP	B:C0000098
(+)	O
(	O
1	O
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
.	O

Neurotoxins	O
such	O
as	O
MPP	O
(+)	O
(	O
1	B:C0000098
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
.	O

Neurotoxins	O
such	O
as	O
MPP	O
(+)	O
(	O
1	O
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	B:C0004112
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
angiotensin	O
II	I:C0003009
.	O

Neurotoxins	O
such	O
as	O
MPP	O
(+)	O
(	O
1	O
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	B:C0003017
and	O
angiotensin	O
II	I:C0003009
.	O

Neurotoxins	O
such	O
as	O
MPP	O
(+)	O
(	O
1	O
-	I:C0000098
methyl-4-phenylpyridinium	I:C0000098
)	O
can	O
act	O
directly	O
on	O
astrocytes	O
to	O
increase	O
levels	O
of	O
angiotensinogen	O
and	O
angiotensin	B:C0003009
II	I:C0003009
.	O

Conversely	O
,	O
dopamine	B:C0013030
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	B:C0058698
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	B:C0597295
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	B:C0003017
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	B:C1171362
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	B:C0529330
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	B:C1171362
of	O
AT2	O
receptors	I:C0390423
.	O

Conversely	O
,	O
dopamine	O
,	O
via	O
type	O
-	I:C0058698
2	I:C0058698
(	I:C0058698
D2	I:C0058698
)	I:C0058698
receptors	I:C0058698
,	O
inhibited	O
production	O
of	O
angiotensinogen	O
,	O
decreased	O
expression	O
of	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
(	I:C0529330
AT1	I:C0529330
)	I:C0529330
receptors	I:C0529330
and	O
increased	O
expression	O
of	O
AT2	B:C0390423
receptors	I:C0390423
.	O

In	O
microglia	B:C0206116
,	O
dopamine	O
and	O
dopamine	O
agonists	I:C0178601
also	O
regulated	O
renin-angiotensin	O
system	I:C0035096
activity	O
.	O

In	O
microglia	O
,	O
dopamine	B:C0013030
and	O
dopamine	O
agonists	I:C0178601
also	O
regulated	O
renin-angiotensin	O
system	I:C0035096
activity	O
.	O

In	O
microglia	O
,	O
dopamine	O
and	O
dopamine	B:C0178601
agonists	I:C0178601
also	O
regulated	O
renin-angiotensin	O
system	I:C0035096
activity	O
.	O

In	O
microglia	O
,	O
dopamine	O
and	O
dopamine	O
agonists	I:C0178601
also	O
regulated	B:C1327622
renin-angiotensin	O
system	I:C0035096
activity	O
.	O

In	O
microglia	O
,	O
dopamine	O
and	O
dopamine	O
agonists	I:C0178601
also	O
regulated	O
renin-angiotensin	B:C0035096
system	I:C0035096
activity	O
.	O

First	O
,	O
indirectly	O
,	O
via	O
downregulation	B:C0013081
of	O
the	O
astrocyte	O
-	I:C0003009
derived	I:C0003009
AII	I:C0003009
.	O

First	O
,	O
indirectly	O
,	O
via	O
downregulation	O
of	O
the	O
astrocyte	B:C0003009
-	I:C0003009
derived	I:C0003009
AII	I:C0003009
.	O

Second	O
,	O
via	O
dopamine	B:C0013030
-	O
induced	O
regulation	O
of	O
microglial	O
angiotensin	O
receptors	I:C0034787
.	O

Second	O
,	O
via	O
dopamine	O
-	O
induced	O
regulation	B:C1327622
of	O
microglial	O
angiotensin	O
receptors	I:C0034787
.	O

Second	O
,	O
via	O
dopamine	O
-	O
induced	O
regulation	O
of	O
microglial	B:C0206116
angiotensin	O
receptors	I:C0034787
.	O

Second	O
,	O
via	O
dopamine	O
-	O
induced	O
regulation	O
of	O
microglial	O
angiotensin	B:C0034787
receptors	I:C0034787
.	O

Dopamine	B:C0013030
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	B:C0206116
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	B:C0529330
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	B:C0390423
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	B:C0529330
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	B:C0068355
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	B:C0038836
axis	O
.	O

Dopamine	O
decreased	O
the	O
microglial	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
AT2	O
ratio	O
leading	O
to	O
inhibition	O
of	O
the	O
pro-inflammatory	O
AT1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
/	O
superoxide	O
axis	B:C1522496
.	O

D2	B:C0058698
receptors	I:C0058698
were	O
particularly	O
responsible	O
for	O
microglial	O
renin-angiotensin	O
system	I:C0035096
inhibition	O
in	O
basal	O
culture	O
conditions	O
.	O

D2	O
receptors	I:C0058698
were	O
particularly	O
responsible	O
for	O
microglial	B:C0206116
renin-angiotensin	O
system	I:C0035096
inhibition	O
in	O
basal	O
culture	O
conditions	O
.	O

D2	O
receptors	I:C0058698
were	O
particularly	O
responsible	O
for	O
microglial	O
renin-angiotensin	B:C0035096
system	I:C0035096
inhibition	O
in	O
basal	O
culture	O
conditions	O
.	O

D2	O
receptors	I:C0058698
were	O
particularly	O
responsible	O
for	O
microglial	O
renin-angiotensin	O
system	I:C0035096
inhibition	O
in	O
basal	B:C0205112
culture	O
conditions	O
.	O

D2	O
receptors	I:C0058698
were	O
particularly	O
responsible	O
for	O
microglial	O
renin-angiotensin	O
system	I:C0035096
inhibition	O
in	O
basal	O
culture	B:C0040284
conditions	O
.	O

However	O
,	O
both	O
D1	B:C0178601
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	B:C0178601
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	B:C0529330
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	B:C0068355
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	B:C1522496
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	B:C0023810
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	B:C0023810
;	O
i.e.	O
activated	O
)	O
microglia	O
.	O

However	O
,	O
both	O
D1	O
and	O
D2	O
agonists	I:C0178601
inhibited	O
the	O
angiotensin	O
type	I:C0529330
-	I:C0529330
1	I:C0529330
/	O
NADPH	O
-	I:C0068355
oxidase	I:C0068355
axis	O
in	O
lipopolysaccharide	O
-	O
treated	O
(	O
LPS	O
;	O
i.e.	O
activated	O
)	O
microglia	B:C0206116
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	B:C0201989
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	B:C0001811
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	B:C0021368
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	B:C0242656
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	B:C0027836
renin-angiotensin	O
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	B:C0035096
system	I:C0035096
exacerbation	O
.	O

The	O
results	O
indicate	O
that	O
the	O
decrease	O
in	O
dopamine	O
levels	I:C0201989
observed	O
in	O
early	O
stages	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
and	O
aging	O
may	O
promote	O
neuroinflammation	O
and	O
disease	O
progression	I:C0242656
via	O
glial	O
renin-angiotensin	O
system	I:C0035096
exacerbation	B:C4086268
.	O

